Group 1 - The article highlights the presentation of new clinical data for a medical device treating aortic regurgitation by a Chinese research team at the global transcatheter cardiovascular therapy conference in San Francisco [1] - The "J-VALVE TF transcatheter aortic valve system" demonstrates superior clinical outcomes, including lower rates of cardiac mortality and third-degree atrioventricular block compared to international counterparts, indicating its effectiveness and safety [1] - The innovative design of the "J-VALVE TF valve" addresses key challenges in treating regurgitation, such as anchoring difficulties and high rates of paravalvular leak and pacemaker implantation [1] Group 2 - The conference is one of the largest and most influential transcatheter cardiovascular intervention academic meetings globally, attended by over ten thousand cardiologists and researchers from more than 100 countries and regions [2]
在美展示成果，“中国开始领跑”
中国基金报·2025-10-26 05:49